The Latest
-
Guardant buys MetaSight for $59M upfront to acquire blood test tech
MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.
-
Grail’s multi-cancer early detection test misses study goal
Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in Stage III and IV cancers.
-
Trump sets fresh 10% global tariff — and plans to increase further
The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.
-
Supreme Court invalidates Trump tariffs based on emergency powers
In a 6-3 decision, the court rejected President Trump's claim that a 1977 law gave him the authority to impose broad tariffs globally.
-
Medtronic’s blood pressure device wins coverage nod in Japan
Medtronic is investing in the rollout of the Symplicity Spyral renal denervation procedure, including hiring for new market development roles, CEO Geoff Martha said on an earnings call.
-
Medtronic to cut 81 employees at California diabetes site
As Medtronic prepares to spin out its diabetes business, a spokesperson said the company is considering the structure, capabilities and scale needed to succeed.
-
Senseonics launches automated insulin dosing system with 1-year CGM
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
-
Apple Watch’s hypertension feature may miss some cases, researchers find
The absence of an alert provides limited reassurance, particularly for older adults or people with an elevated risk of high blood pressure, according to the study’s authors.
-
FDA issues early alert on Trividia glucometer issue linked to 114 injuries
Users may receive an error code either due to a test strip error or a very high blood glucose event, Trividia Health said.
-
Medtronic nets FDA clearance for robotic spine system
Called Stealth AXiS, the surgical system builds on Medtronic’s Mazor robotic platform, as the medical device maker takes market share in the $15 billion cranial and spinal technologies sector.
-
Federal judge strikes down FTC rule expanding premerger reporting requirements
The regulation required firms to provide more details ahead of mergers, likely chilling dealmaking. The Federal Trade Commission could appeal the ruling.
-
Danaher to buy Masimo for $9.9B to boost diagnostics portfolio
Masimo’s board considered other potential partners before determining Danaher was an “ideal fit,” executives at the patient monitoring company said.